Table 3.

Interaction Between Gender and Treatment Time in Psychopathology Improvement, Functioning Improvement, and Drug-Related Side Effects

	Risperidone			Olanzapine			Aripiprazole
	Ge	TP	Ge*TP	Ge	TP	Ge*TP	Ge	TP	Ge*TP
PPANSS	0.14	<0.01	0.47	0.54	<0.01	0.05	0.98	<0.01	0.99
NPANSS	0.53	<0.01	0.14	0.59	<0.01	0.92	0.39	<0.01	0.07
GPANSS	0.23	<0.01	0.39	0.49	<0.01	0.40	0.34	<0.01	0.50
PANSS_T	0.15	<0.01	0.47	0.98	<0.01	0.33	0.35	<0.01	0.43
PSP	0.12	<0.01	0.66	0.57	<0.01	0.45	0.86	<0.01	0.69
UKU1	0.12	<0.01	0.68	0.74	0.02	0.83	<0.01	0.06	0.07
UKU2	0.86	<0.01	0.46	0.14	0.26	0.83	0.11	0.02	0.47
UKU3	0.14	0.03	0.37	0.01	0.44	0.22	0.06	0.32	0.27
UKU4	0.03	0.03	0.12	0.04	<0.01	0.42	0.11	0.23	0.73

Note: All represent p values. Significant results are shown in bold.

Abbreviations: Ge, gender; TP, follow-up time; PPANSS, positive PANSS subscale score; NPANSS, negative PANSS subscale score; GPANSS, general PANSS subscale score; PANSS_T, total PANSS score; PSP, Personal and Social Performance Scale score; UKU1, psychotic side effect score; UKU2, neurological side effect score; UKU3, autonomic side effect score; UKU4, dermatological symptoms and sexual functions score.